PURPOSE: This multicenter phase II trial was performed to determine tumor efficacy and tolerance of the oral platinum drug JM216 in patients with small-cell lung cancer (SCLC). PATIENTS AND METHODS: Patients with SCLC limited disease unfit for intensive chemotherapy or those with extensive disease received JM216 120 mg/m(2)/d for 5 consecutive days every 3 weeks. Individual dose escalation to 140 mg/m(2)/d was allowed if toxicity was </= grade 2 according to the National Cancer Institute Common Toxicity Criteria. Tumor response was evaluated according to World Health Organization criteria. RESULTS: Twenty-seven patients were assessable for toxicity and 26 for tumor response. Eighty-eight cycles were administered. Common Toxicity Criteria grade 3 and 4 hematologic toxicities were neutropenia in 15.9% and 3.7%, lymphocytopenia in 47.6% and 17.1%, and thrombocytopenia in 19.5% and 10.3% of cycles, respectively. One patient suffered from neutropenic fever. Nausea, vomiting, and diarrhea were the most common nonhematologic toxicities. Except for grade 4 diarrhea in one patient, no grade 4 nonhematologic toxicity was observed. No severe neurotoxicity or nephrotoxicity was observed. Tumor response rate was 10 of 26 (38%; 95% confidence interval, 19% to 58%), excluding five unconfirmed partial responses. No complete responses were observed. Median overall time to progression was 110 days (range, 5 to 624 days). Median overall survival time was 210 days (range, 5 to 624 days). CONCLUSION: Oral JM216 is active in previously untreated patients with SCLC and shows mild toxicities.
PURPOSE: This multicenter phase II trial was performed to determine tumor efficacy and tolerance of the oral platinum drug JM216 in patients with small-cell lung cancer (SCLC). PATIENTS AND METHODS: Patients with SCLC limited disease unfit for intensive chemotherapy or those with extensive disease received JM216 120 mg/m(2)/d for 5 consecutive days every 3 weeks. Individual dose escalation to 140 mg/m(2)/d was allowed if toxicity was </= grade 2 according to the National Cancer Institute Common Toxicity Criteria. Tumor response was evaluated according to World Health Organization criteria. RESULTS: Twenty-seven patients were assessable for toxicity and 26 for tumor response. Eighty-eight cycles were administered. Common Toxicity Criteria grade 3 and 4 hematologic toxicities were neutropenia in 15.9% and 3.7%, lymphocytopenia in 47.6% and 17.1%, and thrombocytopenia in 19.5% and 10.3% of cycles, respectively. One patient suffered from neutropenic fever. Nausea, vomiting, and diarrhea were the most common nonhematologic toxicities. Except for grade 4 diarrhea in one patient, no grade 4 nonhematologic toxicity was observed. No severe neurotoxicity or nephrotoxicity was observed. Tumor response rate was 10 of 26 (38%; 95% confidence interval, 19% to 58%), excluding five unconfirmed partial responses. No complete responses were observed. Median overall time to progression was 110 days (range, 5 to 624 days). Median overall survival time was 210 days (range, 5 to 624 days). CONCLUSION: Oral JM216 is active in previously untreated patients with SCLC and shows mild toxicities.
Authors: Jeremy Cetnar; George Wilding; Douglas McNeel; Noelle K LoConte; Thomas A McFarland; Jens Eickhoff; Glenn Liu Journal: Urol Oncol Date: 2011-04-11 Impact factor: 3.498
Authors: Suzanne Jones; John Hainsworth; Howard A Burris; Dana Thompson; Eric Raefsky; Valerie Johnson; Sharon Calvert; Cecile Bulanhagui; David Lebwohl; F Anthony Greco Journal: Invest New Drugs Date: 2002-02 Impact factor: 3.850
Authors: C M George; D J Haraf; A M Mauer; S A Krauss; P C Hoffman; C M Rudin; L Szeto; E E Vokes Journal: Invest New Drugs Date: 2001 Impact factor: 3.850
Authors: Srivandana Akshintala; Leigh Marcus; Katherine E Warren; Robert F Murphy; Tristan M Sissung; Anjali Srivastava; Wendy J Goodspeed; Anne Goodwin; Carmen C Brewer; Christopher Zalewski; Kelly A King; AeRang Kim; William D Figg; Brigitte C Widemann Journal: Pediatr Blood Cancer Date: 2015-01-03 Impact factor: 3.167
Authors: Tahir Latif; Laura Wood; Cindy Connell; David C Smith; David Vaughn; David Lebwohl; David Peereboom Journal: Invest New Drugs Date: 2005-01 Impact factor: 3.850